Solid Biosciences

About Solid Biosciences

Solid Biosciences is a life sciences company committed to developing precision genetic medicines for severe neuromuscular and cardiac diseases. The company's creation stems from a deeply personal mission, as it was founded in 2013 by Ilan and Annie Ganot after their son's diagnosis with Duchenne muscular dystrophy (DMD) in 2012. Ilan Ganot, leveraging his previous career in investment banking, alongside co-founders Andrey Zarur and Gilad Hayeem, established the company, initially named SOLID Ventures Management, LLC, to accelerate the development of meaningful treatments for DMD. The family relocated from London to Boston to immerse themselves in the biotech ecosystem, channeling their experience into building a patient-focused enterprise.

The company operates as a publicly traded entity on the Nasdaq (SLDB) after its initial public offering in January 2018, which raised approximately $125 million. Its business model is centered on the research, development, and eventual commercialization of gene therapies. Solid Biosciences generates capital through public offerings and strategic partnerships to fund its extensive R&D activities and clinical trials. The company collaborates with academic institutions like Harvard Medical School and Mayo Clinic, as well as other biotechnology companies such as Phlox Therapeutics, to advance its pipeline.

Solid's portfolio is focused on a range of devastating conditions, including Duchenne, Friedreich’s ataxia, BAG3-mediated dilated cardiomyopathy, and catecholaminergic polymorphic ventricular tachycardia (CPVT). A key product in its pipeline is SGT-003, a next-generation gene therapy for Duchenne. SGT-003 utilizes a proprietary adeno-associated virus (AAV) capsid, AAV-SLB101, designed for enhanced delivery to muscle tissue while reducing liver exposure. This therapy delivers a microdystrophin transgene intended to restore muscle function. Clinical trial data has shown that SGT-003 is well-tolerated and has produced encouraging expression of microdystrophin in patients. Following a merger with AavantiBio in 2022, the company expanded its focus to include a broader range of cardiac and neuromuscular programs, with Bo Cumbo taking over as CEO and Ilan Ganot remaining on the board as a strategic advisor.